Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.
Type:
Grant
Filed:
January 11, 2021
Date of Patent:
October 17, 2023
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Abstract: A primary culture method in which cells contained in a tissue collected from a living body are primary cultured in vitro, in which the cells in the tissue collected from the living body are seeded and cultured on a top surface of a cell structure containing cells constituting a stroma and composed of a single layer or two or more cell layers laminated in the thickness direction.
Type:
Grant
Filed:
February 5, 2020
Date of Patent:
October 10, 2023
Assignees:
TOPPAN PRINTING CO., LTD., JAPANESE FOUNDATION FOR CANCER RESEARCH
Abstract: A cell culture medium for culturing organoid containing at least two types of components selected from the group consisting of insulin-like growth factor 1 (IGH1), fibroblast growth factor 2 (FGF2) and epiregulin (EREG), and at least one type of component among the following components i (to III); i) Wnt agonist, ii) bone morphogenetic protein (BMP) inhibitor, and iii) transforming growth factor-? (TGIF-?) inhibitor.
Abstract: A method of applying heat to living tissue mainly uses a device for performing heat treatment on at least a portion of the living tissue in high-low-high temperature steps. In high temperature step, the temperature of the at least a portion of the living tissue is heated and kept between 39-46° C., and the heating period is no longer than 30 minutes. In low temperature step, the at least a portion of the living tissue is cooled, and the low temperature period should not be greater than a natural cooling time interval. In addition, the low temperature period must also be shorter than the heating period. Thus, the present invention allows the abnormal cells to be selectively restored or apoptotic without damaging the normal cells.
Abstract: In some aspects, disclosed are methods and compositions for disc regeneration and/or repair using one or more components from conditioned media from fibroblasts. In certain cases, conditioned media is obtained from fibroblasts stimulated with one or more opioid receptor antagonists and one or more toll-like receptor agonists. Conditioned media from fibroblasts may be provided in an effective amount to an individual in need thereof.
Abstract: The present disclosure aims to provide a manufacturing method of a cell structure. The manufacturing method comprises producing a coated region in which a culturing surface is coated with a temperature-responsive polymer or a temperature-responsive polymer composition, forming a droplet of a cell suspension in the coated region, and performing cell culturing in the droplet. A surface zeta potential of the coated region is 0 mV to 50 mV.
Type:
Grant
Filed:
September 7, 2021
Date of Patent:
July 11, 2023
Assignee:
NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
Abstract: Disclosures herein are directed to chemically defined animal-derived component free supplements designed for individual cell types that supports the ex vivo growth of cells as well or better than serum, in chemically defined conditions.
Abstract: The present invention relates to a preparation method of a spheroid using human-derived cardiac stem cells and a therapeutic use for ischemic heart disease using the myocardial regeneration effect thereof. The spheroid using the cardiac stem cells provided in the present invention has excellent myocardial differentiation ability and regenerative therapeutic ability as compared to existing cardiac stem cells, and thus may be used for the treatment of ischemic heart disease such as myocardial infarction.
Type:
Grant
Filed:
June 29, 2018
Date of Patent:
July 4, 2023
Assignees:
INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, HIERABIO INC.
Abstract: Methods of tissue grafting, and more particularly methods for enhancing tissue graft revascularization, e.g., host engagement of pre-existing graft blood vessels.
Abstract: The present invention is directed to indirect ultrasonic cavitation-derived perivascular cells, to methods of use of a perivascular cell composition, to a method of processing a tissue and to an apparatus for the processing of a tissue. The methods include the mechanic indirect ultrasonication of a cellular non-structural tissue, and produce a perivascular fraction which includes perivascular cells. The methods of use are directed to the treatment of a variety of diseases and disorders and to the improvement of a tissue in a subject. The apparatus is provided for the processing of cellular non-structural tissue.
Abstract: The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.
Type:
Grant
Filed:
April 26, 2017
Date of Patent:
June 6, 2023
Assignees:
Sapporo Medical University, Nipro Corporation
Abstract: A system and method of isolating extracellular vesicles. The method includes loading one or more of blood or bone marrow into an input port of a concentration system and centrifuging one or more of the blood or bone marrow to separate one or more of red blood cells, platelet poor plasma, or platelet rich plasma/bone marrow concentrate fractions via a centrifuge device. The method further includes pumping one or more of bone marrow/platelet rich plasma fractions and platelet poor plasma fractions into a receptacle of the concentration system and adding a concentrated aqueous two-phase solution to one or more of the bone marrow concentrate/platelet rich plasma fractions and platelet poor plasma fractions.
Abstract: Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.
Abstract: The present invention includes a method of preparing differentiated endodermal cells comprising growing human pluripotent stem cells (hPSC) under serum free conditions for 3 days on a layer of fibronectin or a gelatinous protein layer in the presence of high activin/TGF-? with a GSK3 inhibitor and a PI3K/mTORC inhibitor in a basal differentiation medium; adding a knock out serum replacement to the media starting on day 4 through day 7; and harvesting the endodermal cells grown therein.
Type:
Grant
Filed:
June 3, 2020
Date of Patent:
May 23, 2023
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Abstract: A cell medium for in vitro inducing chondrogenesis or tenogenesis in mesenchymal stem cells (MSCs). The medium is a glucose medium supplemented with at least one growth factor is chosen from the group of fibroblast growth factors (FGF) or the group of transforming growth factors (TGF), and the FGF or TGF is present in a total concentration of between 1 and 15 ng/ml. In both cases, IGF can be added to enhance the induction process. The use of the cell medium, a method for inducing isolated mesenchymal stem cells (MSCs) and a cell composition obtained by the method are also provided.
Type:
Grant
Filed:
November 20, 2019
Date of Patent:
April 25, 2023
Assignee:
BOEHRINGER INGELHEIM VETERINARY MEDICINE BELGIUM
Inventors:
Sarah Yolande Kristel Broeckx, Jan Hilda Marie Jozef Spaas
Abstract: The present invention relates to methods for obtaining skeletal muscle derived cells (SMDC), and the use of SMDCs in a method of preventing and/or treating neuromyopathies and/or myopathies, wherein the neuromyopathy and/or myopathy is incontinence, in particular a urinary and/or an anal or fecal incontinence.
Type:
Grant
Filed:
December 14, 2018
Date of Patent:
April 4, 2023
Assignee:
INNOVACELL AG
Inventors:
Marco Thurner, Eva Margreiter, Wolfgang Schwaiger, Faheem Muhammad Asim, Rainer Marksteiner
Abstract: The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization.
Type:
Grant
Filed:
October 1, 2019
Date of Patent:
April 4, 2023
Assignees:
The Trustees of the University of Pennsylvania, Massachusetts Institute of Technology
Inventors:
Christopher S. Chen, Jan D. Baranski, Ritika Chaturvedi, Michael T. Yang, Kelly Stevens, Sangeeta Bhatia
Abstract: Improved hybrid neurovascular spheroids and methods for making the same are provided. In some embodiments of a method for making a hybrid neurovascular spheroid, the method includes i) propagating cortical cells to form a cortical spheroid; ii) propagating endothelial cells to form an endothelial spheroid; iii) propagating mesenchymal stem cells to form a mesenchymal cell culture; and iv) combining the cortical spheroid, endothelial spheroid, and mesenchymal spheroid under conditions to form the hybrid neurovascular spheroid.
Type:
Grant
Filed:
March 17, 2020
Date of Patent:
March 28, 2023
Assignee:
The Florida State University Research Foundation, Inc.
Abstract: A viable disc regenerative composition has a micronized material of nucleus pulposus and a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and wherein the mixture is compatible with biologic function and further includes non-expanded whole cells. The biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue. The viable disc regenerative composition extends regenerative resonance that compliments or mimics disc tissue complexity.
Type:
Grant
Filed:
October 15, 2020
Date of Patent:
March 21, 2023
Assignee:
Vivex Biologies Group, Inc.
Inventors:
Harry Thomas Temple, Timothy Ganey, Stephanie Gonzalez, Tracy Scott Anderson, Shabnam Namin